Metraipolis › archive › dc_0983cae71ed4

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938) — Europe PMC PMID:41160399

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41160399
DOI
10.1002/cncr.70157
License (as archived)
solo-consultazione
Archived
2026-11-08T20:40:06.619Z
SHA-256 of the archived text
55727ceeecc97af229ce29a8a23e85ce285cf71c4c1e6ee9b318c255d77d505e
Stable URL of this page
https://metraipolis.com/documento/dc_0983cae71ed4

How to cite

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938) — Europe PMC PMID:41160399 — Europe PMC (en), https://europepmc.org/article/MED/41160399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0983cae71ed4 (Metraipolis archive dc_0983cae71ed4, sha256 55727ceeecc97af229ce29a8a23e85ce285cf71c4c1e6ee9b318c255d77d505e)
BibTeX
@misc{dc0983cae71ed4,
  title = {Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938) — Europe PMC PMID:41160399},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41160399},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0983cae71ed4; sha256 55727ceeecc97af229ce29a8a23e85ce285cf71c4c1e6ee9b318c255d77d505e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41160399. Agents can read the archived copy with the MCP tool read_document.